Tony Coles, M.D., has served as the Chairperson of our board of directors since December 2018 and previously was also the chief executive officer of Cerevel from September 2019 to June 2023.
Prior to joining Cerevel, Dr. Coles co-founded and served as the chairperson and chief executive officer of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases. Before co-founding Yumanity Therapeutics, Dr. Coles served as the chairperson and chief executive officer of TRATE Enterprises, LLC, a privately-held company.
Previously, Dr. Coles served as president, chief executive officer and chairperson of the board of Onyx Pharmaceuticals, Inc. until its acquisition by Amgen. Prior to joining Onyx Pharmaceuticals, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held several executive positions at Bristol-Myers Squibb Company and positions of increasing responsibility at Merck & Co., Inc. In addition to having previously served as a director of Onyx and NPS, Dr. Coles was formerly a director of CRISPR Therapeutics AG, Laboratory Corporation of America Holdings, Campus Crest Communities, Inc. and McKesson Corporation. He also previously served as a member of the Harvard Medical School Board of Fellows.
Dr. Coles currently serves on the board of directors of Regeneron Pharmaceuticals, Inc. and is a member of the Board of Trustees for Johns Hopkins University. He is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the Board of Trustees of The Metropolitan Museum of Art in New York; and a member of the Board of Directors of the Council on Foreign Relations, an independent, non-partisan membership organization, think tank and publisher. In 2022, Dr. Coles was inducted into the American Academy of Arts & Sciences.
Dr. Coles earned his bachelor’s degree at Johns Hopkins University, a medical degree from Duke University, and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.
What is Anthony Coles' net worth?
The estimated net worth of Anthony Coles is at least $664,145.86 as of March 4th, 2024. Dr. Coles owns 15,638 shares of Cerevel Therapeutics stock worth more than $664,146 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Coles may own. Additionally, Dr. Coles receives a salary of $1,140,000.00 as Director at Cerevel Therapeutics. Learn More about Anthony Coles' net worth.
How old is Anthony Coles?
What is Anthony Coles' salary?
How do I contact Anthony Coles?
Has Anthony Coles been buying or selling shares of Cerevel Therapeutics?
Anthony Coles has not been actively trading shares of Cerevel Therapeutics over the course of the past ninety days. Most recently, N Anthony Coles sold 50,000 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $41.01, for a transaction totalling $2,050,500.00. Following the completion of the sale, the director now directly owns 15,638 shares of the company's stock, valued at $641,314.38. Learn More on Anthony Coles' trading history.
Who are Cerevel Therapeutics' active insiders?
Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.
Are insiders buying or selling shares of Cerevel Therapeutics?
In the last year, Cerevel Therapeutics insiders bought shares 4 times. They purchased a total of 6,462,597 shares worth more than $147,510,898.72. In the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 625,260 shares worth more than $21,054,440.60. The most recent insider tranaction occured on March, 4th when Director N Anthony Coles sold 50,000 shares worth more than $2,050,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company.
Learn More about insider trades at Cerevel Therapeutics. Information on this page was last updated on 3/4/2024.
